Trial Profile
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; ZN c5 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Zeno Alpha
- 05 Jan 2023 Status changed from active, no longer recruiting to completed.
- 20 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2021 This trial has been discontinued in Bulgaria, according to European Clinical Trials Database record.